These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30094808)

  • 1. Regulatory Frameworks in Times of Uncertainty.
    Breckenridge A
    Clin Pharmacol Ther; 2019 Mar; 105(3):553-554. PubMed ID: 30094808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
    Danese S; Schabel E; Ainsworth MA; Peyrin-Biroulet L
    Gut; 2020 Jul; 69(7):1157-1161. PubMed ID: 32179569
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent Advances in Drug Development and Regulatory Science in China.
    Chen J; Zhao N
    Ther Innov Regul Sci; 2018 Nov; 52(6):739-750. PubMed ID: 29714583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
    Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
    Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marketing authorisation applications submitted to the European Medicines Agency by small and medium-sized enterprises: an analysis of major objections and their impact on outcomes.
    Amaouche N; Casaert Salomé H; Collignon O; Santos MR; Ziogas C
    Drug Discov Today; 2018 Oct; 23(10):1801-1805. PubMed ID: 29953957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demystifying biosimilars: development, regulation and clinical use.
    Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
    Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease.
    Schuck RN; Pacanowski M; Woodcock J; Zineh I
    Nat Rev Drug Discov; 2018 Feb; 17(2):79-80. PubMed ID: 29269943
    [No Abstract]   [Full Text] [Related]  

  • 8. Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives.
    Marshall S; Madabushi R; Manolis E; Krudys K; Staab A; Dykstra K; Visser SAG
    CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):87-96. PubMed ID: 30411538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
    Rowe-Rendleman CL
    Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.
    Khan S; Carter M
    Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582
    [No Abstract]   [Full Text] [Related]  

  • 11. Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?
    Richardson E; Daniel G; Joy DR; Kweder SL; Maloney DM; Raggio MJ; Jarow JP
    Ther Innov Regul Sci; 2018 Nov; 52(6):793-798. PubMed ID: 29714587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meeting Report: PMDA Public Workshop on Pharmacometrics at Japan.
    Kijima S; Ochiai Y; Ishiguro A
    CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):550-552. PubMed ID: 32914930
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar and mimics: Latin America biosimilar regulations.
    Lizarraga A; Mysler E
    Int J Rheum Dis; 2019 Jan; 22(1):6-8. PubMed ID: 30689310
    [No Abstract]   [Full Text] [Related]  

  • 15. PMDA's Vision for Horizon Scanning of Emerging Technologies Potentially Relevant to the Development of New Medical Products: The Regulatory Challenge.
    Shimokawa M; Sato D; Wakao R; Arai H
    Clin Pharmacol Ther; 2021 Feb; 109(2):295-298. PubMed ID: 33469964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.
    Selker HP; Eichler HG; Stockbridge NL; McElwee NE; Dere WH; Cohen T; Erban JK; Seyfert-Margolis VL; Honig PK; Kaitin KI; Oye KA; D'Agostino RB
    Clin Pharmacol Ther; 2019 Apr; 105(4):857-866. PubMed ID: 30610746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
    Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
    Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of peptide therapeutics: A nonclinical safety assessment perspective.
    Mitra MS; DeMarco S; Holub B; Thiruneelakantapillai L; Thackaberry EA
    Regul Toxicol Pharmacol; 2020 Nov; 117():104766. PubMed ID: 32827570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resuscitating Cardiovascular Drug Development.
    Helmy K; Harrington RA; Kocher B
    JAMA Cardiol; 2017 Dec; 2(12):1295-1296. PubMed ID: 29117283
    [No Abstract]   [Full Text] [Related]  

  • 20. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.